Atlas Trials

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Clinical trial NCT05627245 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05627245
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent Follicular LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRefractory Follicular LymphomaRefractory Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Start date
2023-03-01
Primary completion
2026-09-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.